Trump atrage industria farmaceutică în SUA. Europa riscă să piardă investiții și medicamente

European pharmaceutical companies warn of potential investment losses to the U.S. due to new agreements promoting drug price reductions and investments in America. The U.S. has signed nine new deals aimed at encouraging pharmaceutical firms to launch new drugs at similar prices to Europe while avoiding tariffs. This trend may lead companies to prioritize the U.S. market for research and production, impacting European patients. The EU is monitoring these developments closely, as it seeks to ensure timely access to affordable medications for its citizens.